By Pat Anson, Editor
It was one year ago that Millennium Laboratories introduced a new genetic test that one doctor hailed as the “Holy Grail” of patient drug therapy: a test that could tell physicians why some patients react poorly or differently to pain medication.
Some even predicted it would revolutionize the field of pain management.
Flash forward a year to PAINWeek in Las Vegas, the same health care conference where Millennium announced the launch of its pharmacogenetic (PGT) test in 2012.
At a breakfast symposium attended by hundreds of pain management practitioners, a Millennium representative asked for a show of hands. How many had used the PGT test in the past year?
Only a handful of hands went up.
The revolution is off to a slow start.
“We know that managing pain patients is a trial and error approach many times,” says Jennifer Strickland, PharrmD, Millennium’s vice president of clinical strategy.
“I think that as the literature evolves and as we learn more about this area, it will become more standard of care.”
Read more at National Pain Report.
(0) Readers Comments
November 12, 2012
October 08, 2012
September 12, 2012
July 23, 2012
June 26, 2019
June 26, 2019
Oh boy...Your right we hate to hear this. You know why people in pain
Doesn't the 1.5 billion is spent a year give credence to its possitive
Many MS drugs cause PML and deaths too these drugs all need t
I knew him when he was breaking in at a couple of Los Angeles TV stati
Saying there is a 'twist' is the worst type of spoile